GSK, MMV filing for Kozenis (tafenoquine) in paediatric populations with Plasmodium vivax malaria accepted by Australian Therapeutic Goods Administration 08 Jan 2021
GSK and MMV present positive data on treatment for Plasmodium vivax malaria in children from 6 months up to 15 years of age 19 Nov 2020
Event Highlights from the VivAccess Hosted Symposium at Virtual ASTMH: Accelerating New Tools for Radical Cure of Vivax Malaria from Clinical and Operational Research to Policy 18 Nov 2020
Thailand becomes first malaria-endemic country in Asia-Pacific to approve tafenoquine for radical cure of P. vivax malaria 24 Apr 2020
Solicitud de propuesta - Desarrollo de comprimidos de dosis baja de primaquina en una formulación adaptada a los niños 08 Jan 2020
Country leaders pledge to boost malaria innovation and access to new and existing antimalarials 11 Nov 2019